Core Insights - Exagen Inc. reported record total revenue of $66.6 million for the year ended December 31, 2025, representing a 20% increase compared to 2024 [6][4] - The company achieved over 11% growth in test volume for its AVISE CTD product, supported by new biomarkers and an expanded sales force [1][6] - The average selling price (ASP) for AVISE CTD increased to $441 per test, up by $30 or 7% from the previous year [6][4] Financial Performance - For Q4 2025, revenue was $16.6 million, compared to $13.7 million in Q4 2024 [2][17] - Gross margin for the year was 58.3%, with operating expenses totaling $52.9 million [2][17] - The net loss for the year was $19.9 million, compared to a net loss of $15.1 million in 2024 [2][17] Business Highlights - The company supported the diagnosis and management of care for over 137,000 patients tested by AVISE CTD [6] - Exagen launched novel biomarkers for T-Cell and seronegative rheumatoid arthritis, enhancing its AVISE CTD platform [6][4] - The leadership team was strengthened with the appointment of Michael Mahler, PhD, as Chief Scientific Officer [6] Financial Outlook - Exagen expects full-year 2026 revenue to be in the range of $70 million to $73 million [5]